lancet-header

Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.

Immune Characteristics Predict Outcome of Severe and Critical COVID-19 Patients

25 Pages Posted: 20 Apr 2020

See all articles by Li Yang

Li Yang

Zhengzhou University - Biotherapy Center

Jianjun Gou

Zhengzhou University - Department of Clinical Laboratory

Jianbo Gao

Zhengzhou University - Department of Radiology

Lan Huang

Zhengzhou University - Biotherapy Center

Zhiqiang Zhu

Zhengzhou University - Department of Emergency Medicine

Chao Lan

Zhengzhou University - Department of Emergency Medicine

Yuming Du

Zhengzhou University - Intensive Care Unit

Shaofei Ji

Orthopaedic Hospital of Zhengzhou City - Emergency Intervention Department

Xinfeng Chen

Zhengzhou University - Biotherapy Center

Shasha Liu

Zhengzhou University - Biotherapy Center

Hongchun Liu

Zhengzhou University - Department of Clinical Laboratory

Li-Hua Xing

Zhengzhou University - First Affiliated Hospital

Mengying Yao

Zhengzhou University - Department of Respiratory

Yi Zhang

Zhengzhou University - Biotherapy Center

More...

Abstract

Background: Recently, the novel coronavirus (COVID-19) has broken out worldwide, with rapid increase of infected patients in severe and critical conditions. Immune patterns are considered to be closely associated with disease progression of patients. This study is aimed to evaluate the correlation between immune characteristics and clinical parameters in severe and critical COVID-19 patients.

Methods: Thirty-six severe and critical types of adult cases with COVID-19 were enrolled from February to March, 2020, and 36 healthy donors were used as control. We detected lymphocyte subpopulations and levels of cytokines in peripheral blood of these patients by using flow cytometer. The basic information, disease outcome, computed tomography imaging, (1,3)-β-D-glucan detection (G test), microbiota infection, coagulation profile (eg, D-Dimer), and serum biochemical test evaluated liver, renal and heart function, including aspartate aminotransferase, g-glutamyl trans peptidase, urea, creatine kinase, lactate dehydrogenase of all these patients were also collected.

Findings: We found that cell numbers in these patients were obviously decreased compared to control, including total lymphocytes, total T, CD4+ T, CD8+ T, B and NK cells, particularly in T cells. CD4+/CD8+ T cell ratio in these COVID-19 patients was significantly increased. The cytokine levels, including IL-2, IL-4, IL-6, IL-10, TNF-a and IFN-g, were remarkably increased; especially IL-6 and IL-10 were more elevated. Moreover, patients with high lymphocyte level, excluded B cells, and with low IL-6 or IL-10 level had a good survival. The percentage of patients with high level of lymphocytes was markedly higher in live patients than that in died patients, but an opposite result for B cells; patients with low level of IL-6 and IL-10 were basically live. Meanwhile, patients with low level of lymphocytes were easy to infect with microbiota. Lastly, IL-6 or IL-10 level was closely correlated with D-Dimer and organ dysfunction biomarkers.

Interpretation: Collectively, severe and critical COVID-19 patients exhibit lymphopenia and high level of cytokines, especially impaired T cells, and increased IL-6 or IL-10, which are served as potential biomarkers for disease progression. Therefore, improving lymphopenia and targeting cytokines should be the effective therapeutic strategies for severe and critical COVID-19 patients.

Funding Statement:This work was supported by grants from the Emergency Prevention and Control of COVID-19 Project of Henan Province (No. 201100310900), the National Natural Science Foundation of China (No. 91942314, U1804281, 81602024), Funding from State's Key Project of Research and Development Plan (No. 2018YFC1313400, 2016YFC1303500).

Declaration of Interests: The authors declare no competing interests.

Ethics Approval Statement: This study was approved by the institutional review board at the First Affiliated Hospital of Zhengzhou University.

Keywords: the novel coronavirus (COVID-19); immune characteristic; lymphocyte; cytokine; prognosis

Suggested Citation

Yang, Li and Gou, Jianjun and Gao, Jianbo and Huang, Lan and Zhu, Zhiqiang and Lan, Chao and Du, Yuming and Ji, Shaofei and Chen, Xinfeng and Liu, Shasha and Liu, Hongchun and Xing, Li-Hua and Yao, Mengying and Zhang, Yi, Immune Characteristics Predict Outcome of Severe and Critical COVID-19 Patients (4/2/2020). Available at SSRN: https://ssrn.com/abstract=3569890 or http://dx.doi.org/10.2139/ssrn.3569890

Li Yang

Zhengzhou University - Biotherapy Center

Zhengzhou, Henan 450052
United States

Jianjun Gou

Zhengzhou University - Department of Clinical Laboratory

Zhengzhou, Henan 450002
United States

Jianbo Gao

Zhengzhou University - Department of Radiology ( email )

China

Lan Huang

Zhengzhou University - Biotherapy Center

Zhengzhou, Henan 450052
United States

Zhiqiang Zhu

Zhengzhou University - Department of Emergency Medicine

Zhengzhou, Henan 45002
China

Chao Lan

Zhengzhou University - Department of Emergency Medicine

Zhengzhou, Henan 45002
China

Yuming Du

Zhengzhou University - Intensive Care Unit

Zhengzhou, Henan 450052
China

Shaofei Ji

Orthopaedic Hospital of Zhengzhou City - Emergency Intervention Department

Zhengzhou, Henan
China

Xinfeng Chen

Zhengzhou University - Biotherapy Center

Zhengzhou, Henan 450052
United States

Shasha Liu

Zhengzhou University - Biotherapy Center

Zhengzhou, Henan 450052
United States

Hongchun Liu

Zhengzhou University - Department of Clinical Laboratory

Zhengzhou, Henan 450002
United States

Li-Hua Xing

Zhengzhou University - First Affiliated Hospital ( email )

1 Eastern Jianshe Road
Henan, 450052
China

Mengying Yao

Zhengzhou University - Department of Respiratory ( email )

Zhengzhou, Henan 450052
China

Yi Zhang (Contact Author)

Zhengzhou University - Biotherapy Center ( email )

Zhengzhou, Henan 450052
United States
+86 371 66295320 (Phone)

Click here to go to TheLancet.com

Paper statistics

Downloads
376
Abstract Views
2,679
PlumX Metrics